hydralazine has been researched along with imidazolidines in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chishima, S; Egashira, K; Katoh, M; Mitsui, T; Narita, H; Takeshita, A | 1 |
| Asanuma, H; Hori, M; Kitakaze, M; Kuzuya, T; Minamino, T; Ogai, A; Papst, PJ; Sakata, Y; Terada, N; Ueda, Y | 1 |
2 other study(ies) available for hydralazine and imidazolidines
| Article | Year |
|---|---|
Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Blood Pressure; Coronary Vessels; Enzyme Inhibitors; Gene Expression; Heart Rate; Hydralazine; Imidazoles; Imidazolidines; Immunoenzyme Techniques; Male; Neovascularization, Pathologic; NG-Nitroarginine Methyl Ester; Nitric Oxide; Peptidyl-Dipeptidase A; Plasminogen Activator Inhibitor 1; Rats; Rats, Inbred WKY; Tissue Plasminogen Activator | 2000 |
Inhibition of nitric oxide synthesis induces coronary vascular remodeling and cardiac hypertrophy associated with the activation of p70 S6 kinase in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cardiomegaly; Coronary Vessels; Drug Interactions; Enzyme Activation; Enzyme Inhibitors; Hydralazine; Imidazoles; Imidazolidines; Immunosuppressive Agents; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Rats; Rats, Inbred WKY; Ribosomal Protein S6 Kinases; Sirolimus; Ventricular Remodeling | 2000 |